Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Helsinki University Central Hospital
Helsinki, Finland
- Tampere University Hospital
Tampere, Finland
- Institute Bergonié
Bordeaux, France
- Centre Léon Bérard
Lyon, France
- Institute Paoli-Calmettes
Marseille, France
- Institut de Cancérologie Strasbourg Europe
Strasbourg, France
- Hopital Foch
Suresnes, France
- Institut Gustave Roussy
Villejuif, France
- the Rutherford Cancer Centre, North East
Bedlington, United Kingdom
- Velindre Cancer Centre
Cardiff, United Kingdom
- the Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
- the Rutherford Cancer Centre, North West
Liverpool, United Kingdom
- Charing Cross Hospital
London, United Kingdom
- Royal Marsden Hospital
London, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom
- Royal Preston Hospital
Preston, United Kingdom
- University of Maryland Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland, United States
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative
Buffalo, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Mar 2018
- Primary completion
- 31 Jul 2026
- Completion
- 31 Jul 2026
- Last update posted
- 22 Jul 2025
- Registered enrollment
- 204
- Registry id
- NCT03436485
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.